Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
Add more filters










Publication year range
1.
Oncogene ; 31(35): 3939-48, 2012 Aug 30.
Article in English | MEDLINE | ID: mdl-22139082

ABSTRACT

A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi- and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1-associated alterations of genomic structure evolve during and are required for the development of PCa.


Subject(s)
Chromatin Assembly and Disassembly , DNA Helicases/genetics , DNA Helicases/physiology , DNA-Binding Proteins/genetics , DNA-Binding Proteins/physiology , Gene Deletion , Prostatic Neoplasms/genetics , Animals , Cell Line , Down-Regulation , HEK293 Cells , Homozygote , Humans , Male , Mice , Neoplasm Transplantation , Oligonucleotide Array Sequence Analysis , PTEN Phosphohydrolase/genetics , Polymorphism, Single Nucleotide , RNA Interference , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Transplantation, Heterologous
2.
Cancer Res ; 61(24): 8617-23, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11751373

ABSTRACT

Cyclooxygenase-2 (COX-2) is the inducible isoform of the rate-limiting enzymes that convert arachidonic acid to proinflammatory prostaglandins as well as a primary target for nonsteroidal anti-inflammatory drugs. Accumulating evidence suggests that up-regulation of COX-2 is associated with carcinogenesis in multiple organ systems including the large bowel, lung, breast, and prostate. In this report, we examine the expression of COX-2 protein and mRNA in prostate tissue containing various lesions and in prostate cancer cell lines. In the cell lines, LNCaP, DU145, PC-3, and TSU, COX-2 protein expression was undetectable under basal conditions but could be induced transiently by phorbol ester treatment in PC-3 and TSU cells, but not in DU145 and LNCaP cells. Immunohistochemical analysis of 144 human prostate cancer cases suggested that, in contrast to several previous reports, there was no consistent overexpression of COX-2 in established prostate cancer or high-grade prostatic intraepithelial neoplasia, as compared with adjacent normal prostate tissue. Positive staining was seen only in scattered cells (<1%) in both tumor and normal tissue regions but was much more consistently observed in areas of proliferative inflammatory atrophy, lesions that have been implicated in prostatic carcinogenesis. Staining was also seen at times in macrophages. Western blotting and quantitative RT-PCR analyses confirmed these patterns of expression. These results suggest that if nonsteroidal anti-inflammatory drugs are indeed chemopreventive and/or chemotherapeutic for prostate cancer, their effects are likely to be mediated by modulating COX-2 activity in non-PCa cells (either inflammatory cells or atrophic epithelial cells) or by affecting a COX-2-independent pathway.


Subject(s)
Isoenzymes/biosynthesis , Prostaglandin-Endoperoxide Synthases/biosynthesis , Prostate/pathology , Prostatic Neoplasms/enzymology , Atrophy/enzymology , Blotting, Western , Cyclooxygenase 2 , Disease Progression , Epithelium/enzymology , Epithelium/pathology , Humans , Immunohistochemistry , Isoenzymes/genetics , Male , Membrane Proteins , Prostaglandin-Endoperoxide Synthases/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Stromal Cells/enzymology , Stromal Cells/pathology , Tumor Cells, Cultured , Up-Regulation
3.
Cell Motil Cytoskeleton ; 50(2): 101-13, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11746675

ABSTRACT

Recently, the large filamentous striated-muscle protein titin has been observed in non-muscle cells, and, in one instance, has been proposed to have a nuclear function as a chromosomal component contributing to structure and elasticity. In this study, we sought to further characterize the presumptive nuclear isoform of titin. Immunofluorescence microscopy with multiple titin-specific monoclonal antibodies shows localization to the nucleus in interphase cells and to the spindle machinery in mitotic cells in all cell types examined; localization to condensed chromosomes is not observed. An abundant 700-kDa phosphoprotein is the predominant species immunoprecipitated with these antibodies. Sequencing of peptide fragments of the immunopurified protein reveals identity to AHNAK, a nuclear phosphoprotein, an identification that was confirmed by Western blot analysis with antibodies to AHNAK and peptide fragmentation patterns. Sequence comparison suggests similarities between the repetitive heptad phi+/-phiP+/-phi+/- motif in AHNAK and the PEVK region of titin, potentially explaining the cross-reactivity observed between AHNAK antibodies and titin antibodies. Interestingly, although some AHNAK antibodies stain interphase nuclei, no evidence of mitotic spindle localization is seen, suggesting that the identity of the protein at the latter location is more closely related to titin than AHNAK. This concept is further supported by observations that cell lines not expressing AHNAK have similar antititin antibody localization to the mitotic spindle. We conclude that (1) multiple titin antibodies, particularly those recognizing the PEVK region, cross-react with AHNAK, and (2) the mitotic spindle staining observed with antititin antibodies is most likely due to the association of titin or a titin-like molecule with this structure.


Subject(s)
Cell Nucleus/metabolism , Membrane Proteins/metabolism , Mitosis/physiology , Muscle Proteins/metabolism , Neoplasm Proteins/metabolism , Protein Kinases/metabolism , Spindle Apparatus/metabolism , Amino Acid Motifs/immunology , Amino Acid Sequence , Antibodies/immunology , Antibody Specificity/immunology , Cell Nucleus/ultrastructure , Connectin , Cross Reactions/immunology , Humans , Membrane Proteins/genetics , Membrane Proteins/immunology , Molecular Sequence Data , Molecular Weight , Muscle Proteins/genetics , Muscle Proteins/immunology , Neoplasm Proteins/genetics , Neoplasm Proteins/immunology , Protein Kinases/genetics , Protein Kinases/immunology , Sequence Homology, Amino Acid , Spindle Apparatus/immunology , Spindle Apparatus/ultrastructure
4.
Cancer Res ; 61(16): 5969-73, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11507036

ABSTRACT

Research into molecular and genetic mechanisms underlying familial prostate cancer would be greatly advanced by in vitro models of prostate tumor cells representing primary tumors. We have successfully established an immortalized human prostate epithelial cell culture derived from primary tumors of familial prostate cancer patients with telomerase. The actively proliferating early-passaged 957E cells were transduced through infection with a retrovirus expressing the human telomerase catalytic subunit, human telomerase reverse transcriptase (hTERT). A high level of telomerase activity was detected in 957E/hTERT cells, but not in 957E cells. 957E/hTERT cells are currently growing well at passage 40, whereas 957E cells senesced at passage 5. 957E/hTERT cells exhibit epithelial morphology. Expression of an androgen-regulated prostate specific homeobox gene NKX3.1 and an epithelial cell-specific cytokeratin 8, but not prostate specific antigen or androgen receptor, was detected in 957E/hTERT cells. Prostatic stem cell antigen and p16 were also expressed in this line. 957E/hTERT cells showed growth inhibition when exposed to retinoic acid and transforming growth factor beta1, potent inhibitors of prostate epithelial cell growth. Chromosome analysis showed that the 957E/hTERT cell line (passage 10) was near diploid human male (XY), with most chromosome counts in the 44-46 range. However, there was random loss of chromosomes 8, 13, X, Y, and alteration in chromosome 4q. The late passage 957E/hTERT cell line (passage 32) was karyologically similar to the early passage 957E/hTERT cell line (passage 10) and also had the same alteration of 4q observed in the early passage 957E/hTERT cell line (passage 10) as well as a trisomy of chromosome 20. The well-characterized human cancer lines derived from such patients will be useful for the identification and characterization of prostate cancer susceptibility genes. This is the first documented case of an established human prostate cancer cell line from primary tumor of a familial prostate cancer patient.


Subject(s)
Adenocarcinoma/genetics , Prostatic Neoplasms/genetics , Tumor Cells, Cultured , Adenocarcinoma/enzymology , Adenocarcinoma/pathology , Adult , Cell Division/drug effects , DNA-Binding Proteins , Growth Inhibitors/pharmacology , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Male , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/pathology , Retroviridae/genetics , Reverse Transcriptase Polymerase Chain Reaction , Telomerase/genetics , Telomerase/metabolism , Transduction, Genetic , Transforming Growth Factor beta/pharmacology , Transforming Growth Factor beta1 , Tretinoin/pharmacology
5.
Am J Hum Genet ; 69(2): 341-50, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11443539

ABSTRACT

Multiple lines of evidence have implicated the short arm of chromosome 8 as harboring genes important in prostate carcinogenesis. Although most of this evidence comes from the identification of frequent somatic alterations of 8p loci in prostate cancer cells (e.g., loss of heterozygosity), studies have also suggested a role for 8p genes in mediation of inherited susceptibility to prostate cancer. To further examine this latter possibility, we performed linkage analyses, in 159 pedigrees affected by hereditary prostate cancer (HPC), using 24 markers on the short arm of chromosome 8. In the complete set of families, evidence for prostate cancer linkage was found at 8p22-23, with a peak HLOD of 1.84 (P=.004), and an estimate of the proportion of families linked (alpha) of 0.14, at D8S1130. In the 79 families with average age at diagnosis >65 years, an allele-sharing LOD score of 2.64 (P=.0005) was observed, and six markers spanning a distance of 10 cM had LOD scores >2.0. Interestingly, the small number of Ashkenazi Jewish pedigrees (n=11) analyzed in this study contributed disproportionately to this linkage. Mutation screening in HPC probands and association analyses in case subjects (a group that includes HPC probands and unrelated case subjects) and unaffected control subjects were carried out for the putative prostate cancer-susceptibility gene, PG1, previously localized to the 8p22-23 region. No statistical differences in the allele, genotype, or haplotype frequencies of the SNPs or other sequence variants in the PG1 gene were observed between case and control subjects. However, case subjects demonstrated a trend toward higher homozygous rates of less-frequent alleles in all three PG1 SNPs, and overtransmission of a PG1 variant to case subjects was observed. In summary, these results provide evidence for the existence of a prostate cancer-susceptibility gene at 8p22-23. Evaluation of the PG1 gene and other candidate genes in this area appears warranted.


Subject(s)
Chromosome Mapping , Chromosomes, Human, Pair 8/genetics , Genetic Linkage/genetics , Genetic Predisposition to Disease/genetics , Prostatic Neoplasms/genetics , Age of Onset , Alleles , DNA Mutational Analysis , Female , Gene Frequency/genetics , Genetic Markers/genetics , Genetic Testing , Genotype , Humans , Jews/genetics , Lod Score , Male , Microsatellite Repeats/genetics , Molecular Sequence Data , Mutation/genetics , Odds Ratio , Pedigree , Polymorphism, Single Nucleotide/genetics , Polymorphism, Single-Stranded Conformational , Prostatic Neoplasms/epidemiology , Racial Groups/genetics
6.
Cancer Res ; 61(12): 4683-8, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11406537

ABSTRACT

Critical aspects of the biology and molecular basis for prostate malignancy remain poorly understood. To reveal fundamental differences between benign and malignant growth of prostate cells, we performed gene expression profiling of primary human prostate cancer and benign prostatic hyperplasia (BPH) using cDNA microarrays consisting of 6500 human genes. Frozen prostate specimens were processed to facilitate extraction of RNA from regions of tissue enriched in either benign or malignant epithelial cell growth within a given specimen. Gene expression in each of the 16 prostate cancer and nine BPH specimens was compared with a common reference to generate normalized measures for each gene across all of the samples. Using an analysis of complete pairwise comparisons of expression profiles among all of the samples, we observed clearly discernable patterns of overall gene expression that differentiated prostate cancer from BPH. Further analysis of the data identified 210 genes with statistically significant differences in expression between prostate cancer and BPH. These genes include many not recognized previously as differentially expressed in prostate cancer and BPH, including hepsin, which codes for a transmembrane serine protease. This study reveals for the first time that significant and widespread differences in gene expression patterns exist between benign and malignant growth of the prostate gland. Gene expression analysis of prostate tissues should help to disclose the molecular mechanisms underlying prostate malignant growth and identify molecular markers for diagnostic, prognostic, and therapeutic use.


Subject(s)
Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Humans , Male , Multigene Family , Prostatic Hyperplasia/genetics , Prostatic Hyperplasia/metabolism , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology
7.
Am J Hum Genet ; 68(4): 901-11, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11254448

ABSTRACT

To investigate the relationship between HPC2/ELAC2 and prostate cancer risk, we performed the following analyses: (1) a linkage study of six markers in and around the HPC2/ELAC2 gene at 17p11 in 159 pedigrees with hereditary prostate cancer (HPC); (2) a mutation-screening analysis of all coding exons of the gene in 93 probands with HPC; (3) family-based and population-based association study of common HPC2/ELAC2 missense variants in 159 probands with HPC, 249 patients with sporadic prostate cancer, and 222 unaffected male control subjects. No evidence for linkage was found in the total sample, nor in any subset of pedigrees based on characteristics that included age at onset, number of affected members, male-to-male disease transmission, or race. Furthermore, only the two previously reported missense changes (Ser217Leu and Ala541Thr) were identified by mutational analysis of all HPC2/ELAC exons in 93 probands with HPC. In association analyses, family-based tests did not reveal excess transmission of the Leu217 and/or Thr541 alleles to affected offspring, and population-based tests failed to reveal any statistically significant difference in the allele frequencies of the two polymorphisms between patients with prostate cancer and control subjects. The results of this study lead us to reject the three alternative hypotheses of (1) a highly penetrant, major prostate cancer-susceptibility gene at 17p11, (2) the allelic variants Leu217 or Thr541 of HPC2/ELAC2 as high-penetrance mutations, and (3) the variants Leu217 or Thr541 as low-penetrance, risk-modifying alleles. However, we did observe a trend of higher Leu217 homozygous carrier rates in patients than in control subjects. Considering the impact of genetic heterogeneity, phenocopies, and incomplete penetrance on the linkage and association studies of prostate cancer and on the power to detect linkage and association in our study sample, our results cannot rule out the possibility of a highly penetrant prostate cancer gene at this locus that only segregates in a small number of pedigrees. Nor can we rule out a prostate cancer-modifier gene that confers a lower-than-reported risk. Additional larger studies are needed to more fully evaluate the role of this gene in prostate cancer risk.


Subject(s)
Genetic Linkage/genetics , Genetic Predisposition to Disease/genetics , Neoplasm Proteins/genetics , Prostatic Neoplasms/genetics , Age of Onset , Alleles , Amino Acid Substitution/genetics , Chromosomes, Human, Pair 17/genetics , DNA Mutational Analysis , Exons/genetics , Gene Frequency/genetics , Genetic Testing , Genotype , Humans , Lod Score , Male , Microsatellite Repeats/genetics , Mutation/genetics , Pedigree , Penetrance , Polymorphism, Single Nucleotide/genetics , Prostatic Neoplasms/epidemiology , White People/genetics
8.
Prostate ; 45(4): 323-34, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11102958

ABSTRACT

BACKGROUND: E-cadherin and alpha-catenin are components of adherens junctions which mediate calcium-dependent, cell-cell adhesion in a homotypic manner. Both these molecules have been defined as useful tumor markers as their altered expression correlates with increased tumor aggressiveness and dedifferentiation. More recently, alterations of a third component of adherens junctions, beta-catenin, have been observed to play a role in several human cancers. Dysregulation of beta-catenin, either by direct mutation or by defects in interacting pathways/regulators, can result in its cytoplasmic accumulation and nuclear translocation. In the nucleus, beta-catenin forms a transcriptional complex capable of upregulating target genes, many of which encode proliferative factors. Given its oncogenic activity and connection to human cancer, we examined the beta-catenin gene and its expression in prostate cancer. METHODS: By single-stranded conformational polymorphism (SSCP) and DNA sequencing analyses, we screened exon 3 of beta-catenin from a panel of 81 primary tumors obtained at radical prostatectomy, 22 lymph node metastases from untreated patients, and a unique set of 61 metastatic tissues from 19 patients who died of hormone-refractory disease. RESULTS: We found putative activating mutations (missense and deletion) at a rate of 5% (7/138). One patient had the same 72 base pair deletion in each of nine separate metastases examined, indicating that this change was associated with a clonal population of metastatic cells. CONCLUSIONS: Immunohistological staining of mutation-positive tumors demonstrated beta-catenin accumulation and nuclear localization in a heterogeneous fashion. Consistent with this in vivo finding, our in vitro analyses demonstrate that certain mutations can result in increased beta-catenin nuclear activity in prostate cancer cell lines. These data implicate the beta-catenin signaling pathway in the development of a subset of prostate cancers.


Subject(s)
Cytoskeletal Proteins/genetics , Mutation, Missense , Prostatic Neoplasms/genetics , Sequence Deletion , Trans-Activators , Animals , Cytoskeletal Proteins/biosynthesis , DNA Mutational Analysis , DNA, Neoplasm/genetics , Exons , Humans , Immunohistochemistry , Male , Microscopy, Fluorescence , Neoplasm Metastasis , Neoplasm Staging , Polymorphism, Single-Stranded Conformational , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Transplantation, Heterologous , Tumor Cells, Cultured , beta Catenin
9.
Biochem Biophys Res Commun ; 237(1): 177-81, 1997 Aug 08.
Article in English | MEDLINE | ID: mdl-9266853

ABSTRACT

The cytoplasmic protein alpha-catenin plays a crucial role in E-cadherin mediated cell-cell adhesion by binding E-cadherin to the cytoskeleton via beta- or gamma-catenin and actin. Functional loss of one of these interacting components leads to decreased cell-cell adhesion, and therefore to loss of epithelial integrity. Northern analysis revealed two distinct alphaE-catenin transcripts in different cell lines, whereas apparently only one protein is expressed. Because of the biological importance of this protein we sought to molecularly characterize the differences between the two observed transcripts. cDNA cloning and sequence analysis revealed the earlier described 3.4 kb alphaE-catenin transcript and an alphaE-catenin transcript of approximately 3.8 kb. This larger transcript contains a 321 bp extension in the 3'UTR sequence, which probably arises as a result of alternative polyadenylation. Considering the presence of AU-rich sequences in the extension, it may be involved in mRNA stability.


Subject(s)
Cadherins/biosynthesis , Cytoskeletal Proteins/biosynthesis , Transcription, Genetic , Base Sequence , Cell Line , Cloning, Molecular , Cytoskeletal Proteins/genetics , DNA Primers , DNA, Complementary , Exons , Gene Library , Humans , Male , Molecular Sequence Data , Polymerase Chain Reaction , Prostate , Recombinant Proteins/biosynthesis , alpha Catenin
10.
Cancer Res ; 57(13): 2741-8, 1997 Jul 01.
Article in English | MEDLINE | ID: mdl-9205085

ABSTRACT

Cadherins are a family of calcium-dependent, cell-cell adhesion molecules that play an important morphoregulatory role in a wide variety of tissues. Alterations in cadherin function have been implicated in tumor progression in a number of adenocarcinomas. Despite the increasing number of new cadherins identified, little is known about cadherins in normal renal tissue and renal carcinomas. A novel cadherin transcript, cadherin-6, was recently described to be present in renal cancer cell lines and fetal kidney, but no data on protein expression nor tissue localization has been reported. In this study, we demonstrate that the expression of cadherin-6 is restricted to the proximal tubule epithelium. This finding is critical because these cells give rise to the majority of neoplasms of this organ. Furthermore we demonstrate typical cadherin features of cadherin-6, including cytoplasmic binding to alpha- and beta-catenin. We present data of cadherin-6 expression in a series of 32 primary renal cell cancers. Cadherin-6 expression tended to vary with histology in these samples. Whereas the majority of renal cell cancers with histology-associated poor prognosis (i.e., high grade clear cell carcinomas and sarcomatoid renal tumors) show aberrant expression of cadherin-6, in tumors with a favorable prognosis (i.e., low grade clear cell carcinomas and papillary cancers), normal cadherin-6 expression was predominant. Overall, these findings demonstrate specific expression of cadherin-6 in the proximal renal tubules in normal human kidney and suggest that alterations of cadherin-6 expression are associated with progression of renal cell carcinoma.


Subject(s)
Cadherins/metabolism , Carcinoma, Renal Cell/metabolism , Kidney Neoplasms/metabolism , Kidney Tubules/metabolism , Trans-Activators , Cadherins/immunology , Carcinoma, Renal Cell/diagnosis , Cytoskeletal Proteins/metabolism , Fluorescent Antibody Technique, Indirect , Humans , Immunoblotting , Immunohistochemistry , Kidney Neoplasms/diagnosis , Prognosis , Tissue Distribution , Tumor Cells, Cultured , alpha Catenin , beta Catenin
11.
Genes Chromosomes Cancer ; 19(2): 90-6, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9171999

ABSTRACT

The tumor suppressor gene CDKN2 (p16/MTS1) resides on chromosome 9p21 and encodes a 16 kDa inhibitor of the cyclin-dependent kinases. Inactivation of CDKN2 by homozygous deletion, point mutation, and recently described aberrant methylation in the 5' promoter region may increase progression through the cell cycle in tumors. In this study, we examine the CDKN2 gene for the presence of inactivating alterations in human prostate cancer. Sequence analysis of cell lines revealed no mutation in LNCaP, PC3, and TSU-PR1 and a missense mutation, GAC-->TAC (asp to tyr), in exon 2 of the DU145 cell line at codon 76. No mutations were identified in three primary prostate cancers or in seven lymph node metastases. Loss of heterozygosity (LOH) was analyzed by analysis of microsatellite markers in the vicinity of the CDKN2 gene. LOH was detected in 12 (20%) of 60 primary tumors at one or more loci and in 13 (46%) of 28 metastases. Methylation analysis of the CpG-rich promoter region revealed a dense methylation of CDKN2 in cell lines PC3, PPC1, and TSU-PR1, and this was found to correlate with a lack of mRNA expression by reverse transcription-polymerase chain reaction. A demethylating agent, 5-aza-2'-deoxycytidine, induced reexpression when cells were exposed in vitro. DU145 and LNCaP expressed the CDKN2 transcript and were unmethylated in the promoter region. Three of twenty-four (13%) primary prostate cancers and 1 of 12 metastatic tumors demonstrated promoter methylation. No normal prostate tissues were methylated at the CDKN2 gene promoter. One tumor was found to contain concomitant LOH and promoter methylation indicative of biallelic inactivation. A comprehensive analysis of CDKN2 in prostate cancer reveals that point mutations are infrequent, but gene deletion and methylation combine to inactivate CDKN2 in a subset of tumors. Moreover, alterations in this gene may represent a late event in prostate cancer progression.


Subject(s)
Carrier Proteins/genetics , Chromosome Deletion , DNA Methylation , DNA Mutational Analysis , DNA, Neoplasm/analysis , Prostatic Neoplasms/genetics , Aged , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Cyclin-Dependent Kinase Inhibitor p16 , DNA Modification Methylases , Decitabine , Gene Expression , Heterozygote , Humans , Male , Middle Aged , Neoplasm Metastasis , Polymerase Chain Reaction , Prostatic Neoplasms/pathology , Sequence Analysis, DNA , Tumor Cells, Cultured
12.
Br J Urol ; 79 Suppl 1: 37-43, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9088271

ABSTRACT

Cadherins are a family of calcium-dependent cell-cell adhesion molecules involved in cell-cell aggregation and morphoregulatory cell function. Dysfunction of the cadherin pathway is involved in tumour invasiveness and disease progression for a variety of carcinomas. E-cadherin is a prognostic marker in prostatic cancer, based on the correlation of the grade of E-cadherin expression and tumour grade, stage, metastasis and survival, as well as recurrence after radical prostatectomy. P-cadherin was shown to be lost in all prostatic cancers, although this most likely reflects loss of the basal cell population rather than a transcriptional down-regulation, suggesting that loss of P-cadherin expression is an early event in the tumorigenesis of prostatic carcinomas. Catenins, particularly alpha-catenin, also play an important role in the dysfunction of the cell adhesion complex. Mechanisms of inactivation of the cadherin-catenin pathway include LOH, gene deletions and gene promoter hypermethylation. Therapeutic strategies have been investigated in tumour models, i.e. the use of demethylating agents for the hypermethylated promoter region of E-cadherin or gene transfer in PC-3 cells with homozygous deletion of the alpha-catenin gene. The complexity of neoplastic changes cannot be explained by alterations of cell adhesion molecules alone; but as demonstrated, cadherins and catenins play an important role in this process.


Subject(s)
Cadherins/physiology , Prostatic Neoplasms/pathology , Trans-Activators , Cadherins/metabolism , Cell Adhesion/physiology , Cytoskeletal Proteins , DNA Methylation , Disease Progression , Humans , Male , Prostate/metabolism , Prostatic Neoplasms/metabolism , beta Catenin
13.
Cancer Res ; 56(16): 3814-22, 1996 Aug 15.
Article in English | MEDLINE | ID: mdl-8706029

ABSTRACT

Inactivation of the p53 gene has been implicated in prostate cancer progression. To determine the role of p53 inactivation in the progression of clinical prostatic carcinomas, we assessed 67 tumors derived from patients with clinically localized disease for chromosome 17p and p53 gene allelic loss, p53 gene mutations using single-strand conformational polymorphism and direct sequencing, and p53 protein expression using immunohistochemical staining. Of 55 informative tumors, 10 demonstrated loss of 17p or the p53 gene; however, only a single tumor had a mutation in its remaining p53 allele. Significant p53 overexpression was observed in 2 of 38 tumors, and 9 others had faint staining of a few nuclei ( < 1%). p53 overexpression occurred in no informative tumor with allelic loss or mutation. In a 1-7-year follow-up, positive immunohistochemical staining did not confer an increased risk of recurrence (risk of recurrence, 0.86, P = 0.78), whereas allelic loss of chromosome 17p appeared to be highly correlated with recurrence (risk of recurrence, 3.7, P = 0.003). In an unrelated group of 42 patients with metastatic prostate cancer, p53 overexpression was found in 26 tumors (62%), and 15(36%) had high grade staining. Neither the presence nor the degree of expression correlated with time to progression or time to death. This series suggests that p53 gene inactivation is rare in primary prostatic tumors, not essential to the development of prostate cancer metastases, and of limited use as a prognostic marker in patients with primary or metastatic disease. Another gene or genes on chromosome 17p may be involved in prostate cancer progression.


Subject(s)
Genes, p53 , Mutation , Prostatic Neoplasms/genetics , Base Sequence , Chromosome Deletion , Chromosomes, Human, Pair 17 , Humans , Immunohistochemistry , Male , Molecular Sequence Data , Neoplasm Metastasis , Polymorphism, Single-Stranded Conformational , Tumor Suppressor Protein p53/analysis
14.
Cancer Res ; 55(21): 4813-7, 1995 Nov 01.
Article in English | MEDLINE | ID: mdl-7585512

ABSTRACT

Considerable evidence now exists to support an important role for the E-cadherin-mediated cell-cell adhesion pathway as a suppressor of the invasive phenotype in adenocarcinoma cells. Previous studies have found that this pathway is frequently aberrant in prostate cancers, particularly those that are likely to metastasize. In this study, we report on the effects of re-establishment of this pathway in a prostate cancer cell line, PC-3, in which this adhesion system is dysfunctional by virtue of a deletion of the gene that codes for alpha-catenin, an E-cadherin-associated protein necessary for normal E-cadherin function. Re-expression of alpha-catenin was accomplished either by transfection of PC-3 cells with a copy of the alpha-catenin cDNA under the control of a heterologous promoter or by microcell-mediated transfer of chromosome 5, which contains the alpha-catenin gene and its normal regulatory elements. In both cases, re-expression of alpha-catenin is associated with a similar, dramatic alteration in cell morphology, whereby extensive cell-cell contact is observed. In the case of transfection of the cDNA, this expression is only transient, because the transfected cells either cease to proliferate or, more commonly, revert to the parental phenotype with concomitant cessation of alpha-catenin expression. In contrast, cells containing one or more copies of microcell-transferred chromosome 5 express alpha-catenin in a stable manner and continue to proliferate. Upon injection into nude mice, these latter cells are no longer tumorigenic, or form only slowly growing tumors with greatly extended doubling times when compared to the parental PC-3 cells. During passage in culture, clones that contain only one transferred copy of chromosome 5 reproducibly revert to the parental phenotype. This reversion is associated with loss of the chromosome 5 region containing the alpha-catenin gene and consequent loss of alpha-catenin expression, as well as re-emergence of tumorigenicity. Transfer of chromosome 5 into prostate cancer cells that are E-cadherin negative does not result in either morphological transformation or suppression of tumorigenicity, suggesting that these effects of alpha-catenin expression are dependent upon concomitant expression of E-cadherin. These data demonstrate the tumor suppressive ability of chromosome 5 in the PC-3 prostate cancer cells and suggest that re-expression of alpha-catenin with resultant restoration of E-cadherin function plays a critical role in this process.


Subject(s)
Cadherins/physiology , Chromosomes, Human, Pair 5 , Cytoskeletal Proteins/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Animals , Cell Adhesion/physiology , Cell Communication/physiology , Cell Division/physiology , Cytoskeletal Proteins/physiology , DNA/genetics , Gene Expression , Humans , Male , Mice , Mice, Nude , Phenotype , Transfection , Tumor Cells, Cultured , alpha Catenin
15.
J Vet Intern Med ; 9(3): 149-53, 1995.
Article in English | MEDLINE | ID: mdl-7545754

ABSTRACT

Serum and seminal plasma concentrations or activities of acid phosphatase (AP), prostate specific antigen (PSA), and canine prostate specific esterase (CPSE) were measured in normal dogs, dogs with benign prostatic hyperplasia (BPH), dogs with bacterial prostatitis, and dogs with prostatic carcinoma to determine if these assays would be of value in differentiating dogs with prostatic carcinoma from normal dogs, and dogs with other prostatic disorders. In addition, tissue sections of prostatic adenocarcinomas were stained with antiprostatic AP, anti-CPSE, and anti-PSA antibodies to determine if these would be suitable immunohistochemical markers of prostatic carcinoma. Prostate-specific antigen was not detected in canine serum or seminal plasma. Serum and seminal AP activities did not differ significantly between normal dogs and those with prostatic diseases, or among dogs with different prostatic disorders. Serum CPSE activities were significantly higher in dogs with BPH than in normal dogs. Mean serum CPSE activities in dogs with BPH, bacterial prostatitis, and prostatic carcinoma were not significantly different from each other. Slight to moderate immunohistochemical staining of canine prostatic adenocarcinomas was noted for prostatic AP and PSA; most tumors did not stain for CPSE. These results show that proteins of prostatic origin appear in the serum of dogs as a result of prostatic pathology, especially BPH. Canine prostatic adenocarcinoma does not appear to be associated with significant increases in CPSE or AP activities, possibly because of down-regulation of these enzymes by prostatic carcinoma cells. It is also possible that failure to detect significant differences resulted from limited statistical power for some groups and pairwise analyses because of the small number of dogs evaluated.


Subject(s)
Acid Phosphatase/metabolism , Dog Diseases/diagnosis , Esterases/metabolism , Prostate-Specific Antigen/analysis , Prostatic Diseases/veterinary , Analysis of Variance , Animals , Biomarkers , Dog Diseases/blood , Dog Diseases/enzymology , Dog Diseases/microbiology , Dogs , Evaluation Studies as Topic , Male , Prostatic Diseases/diagnosis , Prostatic Diseases/enzymology , Prostatic Diseases/microbiology , Prostatic Hyperplasia/diagnosis , Prostatic Hyperplasia/veterinary , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/veterinary
16.
Cancer Surv ; 23: 19-32, 1995.
Article in English | MEDLINE | ID: mdl-7621457

ABSTRACT

A number of genetic changes have been documented in prostate cancer, ranging from allelic loss to point mutations and changes in DNA methylation patterns (summarized in Fig. 1). The most consistent changes seen are those of allelic loss events, with the majority of tumours examined showing loss of alleles from at least one chromosomal arm. The short arm of chromosome 8, followed by the long arm of chromosome 16, seem to be the most frequent regions of loss, suggesting the presence of novel tumour suppressor genes. Deletions of one copy of the RB and TP53 genes are less frequent as are mutations of the TP53 gene, and accumulating evidence suggests the presence of an additional tumour suppressor gene on chromosome 17p, which is frequently inactivated in prostate cancer. Alterations in the E-cadherin/alpha catenin mediated cell-cell adhesion mechanism appear to be present in almost half of all prostate cancers and may be critical to the acquisition of metastatic potential of aggressive prostate cancers. Finally, altered DNA methylation patterns have been found in the majority of prostate cancers examined, suggesting widespread alterations in methylation modulated gene expression. The presence of multiple changes in these tumours is consistent with the multistep nature of the transformation process. Finally, efforts to identify prostate cancer susceptibility loci are under way, which may elucidate critical early events in prostatic carcinogenesis.


Subject(s)
Prostatic Neoplasms/genetics , Cadherins/genetics , Cadherins/physiology , Chromosome Deletion , DNA/metabolism , Genes, Retinoblastoma , Humans , Male , Methylation , Oncogenes
17.
World J Urol ; 13(6): 364-8, 1995.
Article in English | MEDLINE | ID: mdl-9116756

ABSTRACT

Alterations in the E-cadherin-mediated cell-cell adhesion pathway are commonly observed in urologic malignancies. This issue has been addressed most thoroughly in prostate cancer. Whereas both cadherin and catenin dysfunction have been seen in human prostate cancers, only down-regulation of E-cadherin has been shown for bladder cancer and renal-cell carcinoma. Although studies in bladder cancer and renal-cell carcinoma are less mature than studies in prostate cancer, they support the hypothesis that immunostaining for E-cadherin may be of significance for both diagnostic and prognostic purposes. Finally, the E-cadherin-mediated cell-cell adhesion pathway may represent a novel chemotherapeutic target for bladder cancer, prostate cancer, and renal-cell carcinoma. Obviously, more work lies ahead to translate these important observations from the bench to the bedside.


Subject(s)
Cadherins/physiology , Cell Communication/physiology , Urologic Neoplasms/physiopathology , Cadherins/chemistry , Carcinoma, Renal Cell/physiopathology , Humans , Kidney Neoplasms/physiopathology , Male , Neoplasm Invasiveness , Prostatic Neoplasms/physiopathology , Structure-Activity Relationship , Urinary Bladder Neoplasms/physiopathology , Urologic Neoplasms/therapy
18.
Semin Oncol ; 21(5): 514-21, 1994 Oct.
Article in English | MEDLINE | ID: mdl-7939745

ABSTRACT

A number of genetic changes have been documented in prostate cancer, ranging from allelic loss to point mutations and changes in DNA methylation patterns (summarized in Fig 1). To date, the most consistent changes are those of allelic loss events, with the majority of tumors examined showing loss of alleles from at least one chromosomal arm. The short arm of chromosome 8, followed by the long arm of chromosome 16 appear to be the most frequent regions of loss, suggesting the presence of novel tumor suppressor genes. Deletions of one copy of the Rb and p53 genes are less frequent as are mutations of the p53 gene, and accumulating evidence suggests the presence of an additional tumor suppressor gene on chromosome 17p, which is frequently inactivated in prostate cancer. Alterations in the E-cadherin/alpha catenin mediated cell-cell adhesion mechanism appear to be present in almost half of all prostate cancers, and may be critical to the acquisition of metastatic potential of aggressive prostate cancers. Finally, altered DNA methylation patterns have been found in the majority of prostate cancers examined, suggesting widespread alterations in methylation-modulated gene expression. The presence of multiple changes in these tumors is consistent with the multistep nature of the transformation process. Finally, efforts to identify prostate cancer susceptibility loci are underway and will hopefully elucidate critical early events in prostatic carcinogenesis.


Subject(s)
Prostatic Neoplasms/genetics , Cadherins/genetics , Cadherins/physiology , Cell Line, Transformed , Cytoskeletal Proteins/genetics , Cytoskeletal Proteins/physiology , DNA, Neoplasm , Gene Expression , Genes, Retinoblastoma , Genes, p53 , Genes, ras , Heterozygote , Humans , Male , Methylation , Oncogenes , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , alpha Catenin
19.
Prostate ; 24(5): 244-51, 1994 May.
Article in English | MEDLINE | ID: mdl-8170837

ABSTRACT

In an effort to stimulate host-mediated antitumor response against prostate cancer in an animal model, highly malignant Dunning MAT-LyLu rat prostate carcinoma cells were transfected with the interleukin-2 (IL-2) cDNA, resulting in their ability to secrete large amounts of biologically active IL-2. Although parental cells form lethal tumors when injected subcutaneously into syngeneic hosts at doses of > or = 5,000, injections of IL-2 secreting cells initially formed tumors and regressed completely in each of over 200 animals at all doses tested (10(4)-8 x 10(7) cells). Mixtures of parental and IL-2 transfected cells were similarly rejected, demonstrating the non-cell autonomous nature of the response. Histological analysis of regressing tumors revealed a vigorous, predominantly lymphocytic and macrophage infiltrate at day 2 and marked tumor necrosis by day 6. Immunohistochemical staining of infiltrating lymphocytes at this latter time point demonstrated numerous T cells bearing either CD4 or CD8 surface markers, suggesting these cells as possibly mediating the tumor rejection. The ability of athymic mice to reject the IL-2 secreting tumor cells, however, suggests a non-T-cell-mediated mechanism. Although splenic natural killer (NK) activity is increased following injection of IL2 secreting tumor cells, this activity appears to be unnecessary for tumor elimination since syngeneic animals injected with asialo-GM1 antiserum to decrease NK activity also rejected IL-2 transfected cells, albeit slightly less effectively than untreated animals. Immunization of animals with subcutaneous injections of IL-2 transfected cells protected animals against a subsequent challenge of 10(4) wild-type cells 1 to 2 weeks later in 19 of 51 cases; however, immunization did not confer protection against larger doses of parental tumor. These studies indicate that high local concentrations of IL-2 stimulate the elimination of large local burdens of prostate cancer in this model system, and this elimination results in a weak, but detectable systemic immune response against wild-type prostate cancer cells.


Subject(s)
Adenocarcinoma/immunology , Immunotherapy, Active , Interleukin-2/immunology , Prostatic Neoplasms/immunology , Transfection , Adenocarcinoma/therapy , Animals , Down-Regulation , Interleukin-2/genetics , Killer Cells, Natural/immunology , Male , Mice , Mice, Nude , Neoplasm Transplantation , Prostatic Neoplasms/therapy , Rats , Rats, Inbred Strains , Tumor Cells, Cultured
20.
Article in English | MEDLINE | ID: mdl-7587126

ABSTRACT

A number of genetic changes have been documented in prostate cancer, ranging from allelic loss to point mutations and changes in DNA methylation patterns (summarized in Fig. 1). To date, the most consistent changes are those of allelic loss events, with the majority of tumors examined showing loss of alleles from at least one chromosomal arm. The short arm of chromosome 8, followed by the long arm of chromosome 16, appear to be the most frequent regions of loss, suggesting the presence of novel tumor suppressor genes. Deletions of one copy of the Rb and p53 genes are less frequent, as are mutations of the p53 gene, and accumulating evidence suggests the presence of an additional tumor suppressor gene on chromosome 17p, which is frequently inactivated in prostate cancer. Alterations in the E-cadherin/alpha-catenin-mediated cell-cell adhesion mechanism appear to be present in almost half of all prostate cancers and may be critical to the acquisition of metastatic potential of aggressive prostate cancers. Finally, altered DNA methylation patterns have been found in the majority of prostate cancers examined, suggesting widespread alterations in methylation-modulated gene expression. The presence of multiple changes in these tumors is consistent with the multistep nature of the transformation process. Finally, efforts to identify prostate cancer susceptibility loci are under way and may elucidate critical early events in prostatic carcinogenesis.


Subject(s)
Prostatic Neoplasms/genetics , Cadherins/genetics , Chromosome Mapping , Chromosomes, Human, Pair 16 , Cytoskeletal Proteins/genetics , DNA, Neoplasm/chemistry , DNA, Neoplasm/genetics , Gene Deletion , Genes, Retinoblastoma , Genes, Tumor Suppressor , Genes, p53 , Genes, ras , Heterozygote , Humans , Male , Methylation , alpha Catenin
SELECTION OF CITATIONS
SEARCH DETAIL
...